<div id="readability-page-1"><p>Acrivon Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock and has a $7.00 price target.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Michael Okunewitch has given his Buy rating due to a combination of factors, including Acrivon’s solid financial runway and encouraging clinical progress with its lead asset, ACR-368. The company ended 1Q26 with close to $100M in cash and investments, which he views as sufficient to fund upcoming value-creating milestones, particularly the continued advancement of the potentially registrational Phase 2 program.</p> <p>He also highlights robust emerging efficacy data for ACR-368 in recurrent high-grade endometrial cancer, with notable response rates in both biomarker-selected and all-comer serous populations, supporting a broad development strategy. Additional upside stems from pipeline diversification, including a dual WEE1/PKMYT1 inhibitor showing early tumor shrinkage with a favorable safety profile, and a differentiated CDK11 program that could validate the AP3 platform and tap into a high-interest AML market.</p> </div>

ACRV

ARKG

SBIO

LABU

<p>Acrivon Pharmaceuticals received a Buy rating from analyst Michael Okunewitch of Maxim Group, with a price target of $7.00. The rating is supported by the company's strong cash position of nearly $100M and promising clinical data for ACR-368 in treating recurrent high-grade endometrial cancer. The company is also diversifying its pipeline with new therapies showing early positive results.</p>

Tip Ranks

Acrivon Therapeutics

SPDR S&P Biotech

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Acrivon Pharmaceuticals: Buy Rating Backed by Strong Cash Runway and Promising ACR-368 Phase 2 Efficacy